RxDoctor Payments Data

Celina Carr, PA

Physician Assistant · Alamo, TXNPI 1508130501

Payments from drug & device makers

$1,830in general payments, 2019–2025

Across 90 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$655
  • Lilly USA, LLC$461
  • Stryker$346
  • AbbVie$156
  • Amgen$110
  • AstraZeneca$66
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$1,830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk33$655
Lilly USA, LLC36$461
Stryker4$346
AbbVie4$156
Amgen7$110
AstraZeneca4$66
Bayer1$20
Axsome Therapeutics, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,830 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$18,663
Medicare patients
52
Services billed
950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$45,109
MounjaroTirzepatide34$35,035
RybelsusSemaglutide16$27,737
JardianceEmpagliflozin26$24,434
FenofibrateFenofibrate,micronized54$1,981
Omeprazole87$1,733
Fluticasone Propionate107$1,434
Atorvastatin Calcium126$1,223
Rosuvastatin Calcium63$997
Levothyroxine Sodium97$918
Lisinopril97$838
Zolpidem Tartrate43$729
Levocetirizine Dihydrochloride33$716
Naproxen92$663
Losartan Potassium80$594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$655$72,84652 claims
Lilly USA, LLCMounjaro$461$35,03534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Alamo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →